Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05338775 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: TRIMM-3
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 55 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Completion pushed from May 3, 2027 to Dec 31, 2027 Show 1 more changeShow less
    • Completion pushed from May 3, 2027 to Dec 31, 2027
  2. 12 versions Re-verified since Aug 7, 2025, no change to tracked fieldsv43-v54
  3. Primary completion date: Apr 30, 2025 to May 22, 2025v42
  4. 3 versions Re-verified since Mar 27, 2025, no change to tracked fieldsv39-v41
  5. Primary completion date: Feb 28, 2025 to Apr 30, 2025 Completion date: Mar 31, 2026 to May 3, 2027v38 Show 1 more changeShow less
    • Completion date: Mar 31, 2026 to May 3, 2027
Show 32 earlier versionsHide 32 earlier versions
  1. 4 versions Re-verified since Dec 4, 2024, no change to tracked fieldsv34-v37
  2. Study Status, Study Descriptionv33
  3. Primary completion date: Sep 21, 2024 to Feb 28, 2025v32
  4. Re-verified, no change to tracked fieldsv31
  5. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 152 to confirmed 74 · Site details revised at 19 of 19 sitesv30 Show 2 more changesShow less
    • Enrollment target: estimated 152 to confirmed 74
    • Site details revised at 19 of 19 sites
  6. Completion date: Nov 28, 2025 to Mar 31, 2026 Study sites revised (19)v29 Show 1 more changeShow less
    • Study sites revised (19)

    See this version in full on ClinicalTrials.gov ↗

  7. Study sites revised (19)v28 See this version in full on ClinicalTrials.gov ↗
  8. Study sites: 18 to 19v27
  9. Study sites revised (18)v26 See this version in full on ClinicalTrials.gov ↗
  10. Re-verified, no change to tracked fieldsv25
  11. Completion date: Oct 15, 2025 to Nov 28, 2025 Study sites revised (18)v24 Show 1 more changeShow less
    • Study sites revised (18)

    See this version in full on ClinicalTrials.gov ↗

  12. Study sites revised (18)v23 See this version in full on ClinicalTrials.gov ↗
  13. Study sites revised (18)v22 See this version in full on ClinicalTrials.gov ↗
  14. Re-verified, no change to tracked fieldsv21
  15. Study sites revised (18)v20 See this version in full on ClinicalTrials.gov ↗
  16. 4 versions Re-verified since Jul 19, 2023, no change to tracked fieldsv16-v19
  17. Study sites: 17 to 18v15
  18. 2 versions Re-verified since May 5, 2023, no change to tracked fieldsv13-v14
  19. Study sites: 20 to 17v12
  20. 4 versions Re-verified since Dec 1, 2022, no change to tracked fieldsv8-v11
  21. Enrollment target: 76 to 152v7
  22. Enrollment target: 152 to 76 Site details revised at 2 of 20 sitesv6 Show 1 more changeShow less
    • Site details revised at 2 of 20 sites
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Trial Details
NCT Number NCT05338775
Lead Sponsor Janssen Research & Development, LLC
Conditions Relapsed/ Refractory Multiple Myeloma
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov